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Oral Presentations 31Background:Little is known about the prevention practices used
by HCT centers internationally to prevent herpesvirus and fungal
infections. The purpose of this survey was to compare prevention
strategies by geographic region, center size and patient population
(pediatric vs. adult).Methods: A web-based questionnaire was dis-
tributed to Program Directors at CIBMTR-affiliated HCT centers
to elicit information on the strategies used to prevent HSV, VZV,
CMV and fungal diseases at each institution between 1999 and
2003. Results: The response rate was 80% (n 5 174) from HCT
centers in 32 countries, including the US/Canada (n5 96), Europe
(n5 40), Australia and New Zealand (n5 13), Latin America (n 5
12), Asia (n5 6), the Middle East (n5 4) and South Africa (n5 3).
While short-course acyclovir (ACV) for HSV prophylaxis was used
almost uniformly, 62% of centers routinely used prophylactic low-
dose ACV or similar agents as prophylaxis against VZV; of these,
19% treated for 1 month or less, 29% for 3–4 mos., 9% for 6–9
mos., 26% for 12 mos. and 17% until off immunosuppressants or
until immune reconstitution. Strategies to prevent CMV disease
in seropositive recipients were used in the following proportions:
high-dose ACV/VACV alone (3%), Ganciclovir-based (GCV) pro-
phylaxis alone (5%), surveillance and preemptive therapy (PET)
alone (47%) or a combination strategy (45%) most commonly
high-dose ACV and PET.The prevention strategies used in Europe
were very similar to those used in theUSwith the exception of high-
dose ACV/VACV which was used routinely by 48% of European
centers compared with 25% of US centers (P\ .05, Fisher exact
test). In Australia and NZ (grouped together), GCV prophylaxis
was used in higher proportions than in the US, Europe and Canada
(54% vs. 23%, P\ .05). Routine antifungal prophylaxis was used by
78% and 57% of European and Canadian centers, respectively,
compared with its use in the US (97%), Australia/NZ (100%),
and Latin America (100%). Also, antifungal prophylaxis was more
commonly used in pediatric centers than in adult-only centers
(97% vs 85%). Practices among smaller centers were remarkably
similar to those in high-volume centers (.50 HCTs annually).
Other trends in prevention strategies will be presented at the con-
ference. Conclusion: This large analysis sheds light on current
practices being employed globally to prevent herpesvirus and fungal
diseases in HCT recipients and highlights previously unknown dif-
ferences in prevention strategies.77
IMPACT OF RIBAVIRIN THERAPY ON RESPIRATORY SYNCITIAL VIRUS
INFECTION FOLLOWING HEMATOPOIETIC CELL TRANSPLANTATION
Kodali, D., Cao, Q., Young, J., Orchard, P., Burns, L.J. University of
Minnesota, Minneapolis, MN.
Respiratory syncitial virus (RSV) infections are associated with
high morbidity and mortality among hematopoietic cell transplan-
tation (HCT) recipients. We conducted a retrospective cohort
study to determine the impact of ribavirin therapy on RSV infec-
tion, defined as respiratory symptoms with a nasopharyngeal (NP)
or bronchial lavage positive RSV assay/culture. Of 3648 HCT re-
cipients between January 1986 and August 2005, 109 (median age
32 years, range 0.6–64) were diagnosed with RSV infection; the
overall incidence was 3% (95% confidence intervals [CI], 2.5–
3.6%). Sixty-nine patients received aerosolized ribavirin therapy
(RT) and 40 did not (noRT). Median follow-up was 1.1 (range 0–
18.6) years and 4.7 (range, 0–20.0) years for the RT and noRT
groups (p 5 .01), respectively. The two groups were comparable
with respect to age, conditioning regimen, gender, donor type, un-
derlying disease, cytomegalovirus serology, transplant year, GVHD
prophylaxis and incidence, time to neutrophil recovery, NP swab
positive assay/culture and evidence of co-infections at time of diag-
nosis of RSV infection. RT patients had a shorter time from trans-
plant to RSV diagnosis (63 vs. 159 days, p\0.01), were less likely to
have neutrophil engraftment (66% vs. 85%, p 5 0.02), and were
more likely to have lower respiratory infection (LRI) as evidenced
by pulmonary infiltrates on CXR (80% vs. 27%, p\0.01). RSV in-
fection resolved in 44 patients (63%) of the RT group compared
with 37 (90%) patients in the noRT group (p 5 0.01); RSV related
deaths occurred in 15 (21%) RT patients and 1 (2%) noRT patient.
In the RT group, patients who failed therapy were more likely tohave LRI (96% vs. 68%, p\ 0.01), lack of neutrophil engraftment
(46% vs. 77%, p 5 0.01), shorter time from transplant to RSV di-
agnosis (17 days vs. 79 days, p5 0.01) and presence of co-infections
(54% vs. 16%, p\0.01).Multivariate analysis revealed the presence
of co-infections as the only predictive factor in lack of resolution of
RSV infection in the RT group (relative risk 2.54, 95% CI 1.49–
4.3). We conclude that RSV infected patients with neutrophil en-
graftment and no evidence of LRI often improve without ribavirin
therapy and can be closely monitored. In contrast, mortality re-
mains high despite ribavirin therapy in patients with LRI, lack of en-
graftment, and co-infections.78
CHRONIC HEPATITIS C, CIRRHOSIS, AND END STAGE LIVER DISEASE
AMONG 30-YEAR SURVIVORS OF BONE MARROW TRANSPLANT
Pergam, S.A.1, Strasser, S.I.2, Flowers, M.E.1, Sullivan, K.M.3,
McDonald, G.B.1. 1Fred Hutchinson Cancer Research Center, Seattle,
WA; 2University of Sydney - AW Morrow Gastroenterology and Liver
Centre, Camperdown, Australia; 3Duke University Medical Center,
Durham, NC.
Introduction: For long-term survivors who received a bonemar-
row transplant (BMT) before the discovery of hepatitis C virus
(HCV), chronic HCV infection is a common complication. We
evaluated a cohort of BMT recipients from the pre-HCV screening
era to determine the frequency of progression to cirrhosis and End
Stage Liver Disease (ESLD) along with relevant risk factors.
Methods: We reviewed the course of a total of 134 patients trans-
planted at the Fred Hutchinson Cancer Center (FHCRC) in Seat-
tle, WA before June 1978 who survived over 10 years after BMT.
We retrospectively collected data using the FHCRC Long-Term
Follow-Up database, which includes data from periodic on-site ex-
aminations, all available outside records, laboratory tests, and yearly
questionnaires. A priori risk factors thought to be associated with
cirrhosis and ESLD were assessed using chi-squared and Wil-
coxon-rank sum analyses. Results: A total of 134 patients met cri-
teria for inclusion in the study, of which 9 were lost to follow-up,
leaving 125 evaluable patients. 82 (66%) were still alive at a median
28.6 years (24.0–35.5); 43 (34%) had died at a median 20.4 years
(10.1–31.9). HCV status was known in 94 survivors: 58 (62%)
were HCV-infected patients, of whom 7 cleared the virus. Among
51 chronically HCV-infected patients, 34 (67%) developed chronic
liver disease. Cirrhosis developed in 14/51 (27%) of these chroni-
cally infected patients, 10 of whom progressed to ESLD. Four total
ESLD patients underwent orthotopic liver transplant, 3 for decom-
pensated cirrhosis and 1 for cirrhosis with hepatocellular carcinoma
(HCC). One other patient with ESLD developed HCC. Cirrhosis
(p\0.01) and ESLD (p 5 0.02) were associated with HCV status,
but not with gender, age at transplant, diagnosis, conditioning ther-
apy, post-BMT immunosuppression, hepatitis B status, history of
graft-versus-host-disease, or history of sinusoidal obstruction syn-
drome. Conclusions: In this unique cohort of long-term survivors
of BMT with over 30 years of follow-up, a large portion of patients
were infected with HCV and most developed chronic HCV infec-
tion. Those with chronic infection are at high risk of developing cir-
rhosis and ESLD. Our data indicate that HCV infection is
a significant cause of morbidity and mortality in these patients.79
PEGFILGRASTIM (P) APPEARS TO BE EQUIVALENT TO MULTIPLE DAILY
DOSES OF FILGRASTIM (F) TO TREAT NEUTROPENIA POST-AUTOLO-
GOUS PERIPHERAL BLOOD STEM CELL TRANSPLANT (PBSCT) IN PA-
TIENTS WITH NON-HODGKIN’S LYMPHOMA: RESULTS OF
A RANDOMIZED PHASE II TRIAL
Rifkin, R., Beveridge, R., Spitzer, G., Orloff, G., Mandanas, R.,
McGaughey, D., Zhan, F., Boehm, K., Asmar, L. Blood and Marrow
Transplant Network, US Oncology, Houston, TX.
Filgrastim has previously been shown to decrease the time to neu-
trophil recovery following autologous PBSCT. Therefore, it was
hypothesized that a single injection of pegfilgrastim (P) would
32 Oral Presentationsmimic the role of filgrastim (F), resulting in at least an equivalent
shortening of post-PBSCT neutropenia.
NHL patients over the age of 18 years who were deemed eligible
for PBSCTwere identified prior to the administration of high-dose
chemotherapy, and following adequate harvest and cryopreserva-
tion of peripheral blood progenitor cells (ie, . 2.5  106 CD341
cells/kg). Eligible patients with preserved end organ function re-
ceived either standard BEAM or BEAC high-dose chemotherapy.
Prior to high-dose therapy, patients were randomly assigned to re-
ceive either P at a fixed-dose of 6 mg onDay11(Arm A), or weight-
based, dose-adjusted F rounded to the nearest prefilled syringe be-
ginning on Day 11(Arm B) following transplantation.
One-hundred one eligible patients were enrolled within US On-
cology Transplant Network between July 2003 and April 2007.
Three patients were deemed ineligible (CHF death, consent with-
drawn, other). The analyses and results presented below outline
the remaining 98. The demographic characteristics of both arms
were well-balanced with regards to stage at diagnosis and treatment,
ECOG Performance Status, histology, and lines of prior therapy.
The comparison of P vs F is summarized in the table that follows.
Transplant-related mortality and the incidence of Grade 3–4 ad-
verse events were comparable in both arms.
In conclusion, administration of pegfilgrastim post-PBSCT ap-
pears to be equivalent to multiple daily doses of filgrastim. Such
an approach might be considered in lieu of filgrastim thereby obvi-
ating the need for multiple daily injections.
Comparison of Pegfilgrastim (P) versus Filgrastim (F)
Arm A Arm B
Variable (Pegfilgrastim) (Filgrastim)No. of Patients Treated (n) 50 48
Doses Received (mean ± SD) 1.0 ± 0 12.7 ± 2.6
ANC Recovery (days) (mean ± SD) 8.3 ± 1.1 8.9 ± 1.5
RBC Transfusions (mean ± SD) 1.7 ± 0.9 1.9 ± 1.2
Platelet Transfusions (mean ± SD) 3.0 ± 1.9 2.8 ± 1.8
Positive Blood Culture Rate (%) 18.0% 29.0%
Febrile Neutropenia Rate (FN) (%) 18.0% 16.7%
Duration of FN (days) (mean ± SD) 5.1 ± 3.4 5.5 ± 4.980
PRIMARY CMV INFECTION IN CMV SERONEGATIVE RECIPIENTS OF
A STEM CELL PRODUCT FROM A SEROPOSITIVE DONOR (D1/R-): FRE-
QUENCY OF AND RISK FACTORS FOR TRANSMISSION
Sandhu, R.K., Smith, J., Kirby, K.A., Heimfeld, S., Corey, L.,
Boeckh, M. Fred Hutchinson Cancer Research Center, Seattle, WA.
Background: To evaluate if there is an effect of host and donor
factors in developing primary CMV infection in CMV D1/R- he-
matopoietic stem cell transplant (HCT) recipients. Method: Be-
tween 1/1996 and 12/2006, 392 D1/R- patients undergoing 1st
allogeneic HCT were evaluated retrospectively for host and donor
factors that may affect CMV transmission (recipient and donor age,
race, sex, and ABO type, stem cell source, stem cell types [CD14,
CD34, mononuclear cells] and overall number, underlying disease
risk, conditioning regimen, GVHD prophylaxis, acute GVHD,
TBI). Patients were evaluated for CMV antigenemia (AG) and/or
DNAemia until day 100 after HCT. Factors associated with
CMV transmission were evaluated by Cox regression models. All
patients received preemptive antiviral therapy for AG positivity.
Results:Of 392 D1/R- patients 383 (97.7%) were monitored reg-
ularly (AG: 345, AG and PCR: 29, PCR: 9) while and 9 (2.3%) were
not tested because of early death. By day 100, 57 patients (14.5%)
became antigenemia or PCR positive (50/345 [14.5%] by AG, 7/
29 [24.2%] by AG and PCR, and 0% by PCR only); 3 additional pa-
tients became positive at sites other than blood. CMV disease oc-
curred in 13 patients (3.3%) at a median of 111 days after HCT
(range 19–617 days). Of these, 6 cases occurred before day 100 (in-
cidence 1.5%) and 7 after day 100 (2.2%of patients alive at day 100).
Five patients with CMV disease after day 100 had CMV infection
diagnosed before day 100, resulting in an incidence of 8.8% among
those with early CMV infection. No statistically significant risk fac-
tors for CMV transmission via blood or marrow were identified.
However, ABO blood group B (hazard ratio 0.2, 95% CI 0.1–1.0,P 5 0.05, compared to all other groups) and the total number of
cells/kg transfused (HR 1.8, 95%0.9–3.8, P5 0.09, for values above
the 90th percentile) were borderline significant in multivariable
models. Conclusions: Transmision of CMV via marrow or stem
cells is uncommon. Although no significant risk factors were iden-
tified, the observed trends for cell counts and ABO blood groups
are interesting and suggest that the inoculum and perhaps genetic
factors may be important in determining transmission risk.
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PERFORMANCE STATUS, BUT NOT THE HEMATOPOIETIC CELL TRANS-
PLANTATION COMORBIDITY INDEX (HCT-CI), PREDICTS MORTALITY
AT A CANADIAN TRANSPLANT CENTRE
Guilfoyle, R.1, Demers, A.2, Richardson, E.3, Bredeson, C.4, Seftel, M.1,3.
1University of Manitoba, Winnipeg, MB, Canada; 2CancerCare Mani-
toba, Winnipeg, MB, Canada; 3CancerCare Manitoba, Winnipeg, MB,
Canada; 4Medical College of Wisconsin, Milwaukee, WI.
Introduction: The hematopoietic cell transplantation-specific
comorbidity index (HCT-CI) was developed at a single centre in or-
der to predict outcomes for allogeneic transplant recipients who
have comorbidities. This index had a higher predictive power for
non-relapse mortality (NRM) and overall survival (OS) than other
tools such as the Charlson Comorbidity Index. The HCT-CI has,
to our knowledge, not been validated in unselected transplant recip-
ients at an institution outside the US. We evaluated whether the
HCT-CI predicts NRM and OS at a Canadian institution and
whether other readily available pre-transplant variables can predict
NRM andOS.Methods:Using a prospective cohort design, we an-
alyzed consecutive adult allogeneic HCT recipients between 01/
1990 and 12/2005. Comorbidity was scored according to the
HCT-CI. Kaplan-Meier survival curves were generated and hazard
ratios were calculated using the Cox model. Results: Of 187 pa-
tients, 64 had AML or MDS, 40 had CML, and 83 had other diag-
noses. Preparative regimens were myeloablative in 177 (95%).
Grafts were from related donors in 138 (74%). Stem cell source
was marrow in 134 (72%), peripheral blood in 51 (27%), and
both in 2 (1%). HCT-CI risk was low in 22 (12%), intermediate
in 50 (27%) and high in 104 (55%). Two year OS was 45% (95%
CI: 24%-64%), 55% (95% CI: 40%-68%), and 42% (95% CI:
32%-51%) in the low, intermediate and high risk HCT-CI groups
respectively. Two year NRM was 40% (95% CI: 21%-65%), 28%
(95%CI: 17%-43%), and 34% (95% CI: 25%-44%) in the low, in-
termediate, and high risk groups, respectively. In both univariate
andmultivariate analyses, theHCT-CI was not a significant predic-
tor of OS or NRM. In contrast, a KPS of\ 90% at HCT was
a strong predictor of post HCT OS and NRM. Conclusions:
The HCT-CI failed to predict NRM or OS at a Canadian trans-
plant institution. In contrast, KPS appeared to be a powerful inde-
pendent indicator of post-transplant survival.We suggest that large,
multicentre studies are required before the HCT-CI can be applied
in clinical practice.82
SEVERE HEMORRHAGIC CYSTITIS (HC) AFTER ALLOGENEIC HEMATO-
POEITIC STEM CELL TRANSPLANTATION (HSCT): INCIDENCE AND
RISK FACTORS
Smith, A.R.1, Tolar, J.1, DeFor, T.E.3, Weisdorf, D.J.2,
MacMillan, M.L.1. 1University of Minnesota, Minneapolis, MN; 2Uni-
versity of Minnesota, Minneapolis, MN; 3University of Minnesota, Min-
neapolis, MN.
HC is a major source of morbidity after HSCT. Severe HC often
results in prolonged hospitalizations, increased health care costs,
decreased quality of life and, rarely, death. Further elucidating
risk factors may lead to preventive strategies and early treatment.
We reviewed 208 cases of HC which occurred in 1353 allogeneic
HSCT recipients transplanted at the University of Minnesota
from 1995–2006. Severe HC was defined as urinary clots and blad-
der pain requiring bladder irrigation and/or sequelae such as ure-
thral and/or ureteral obstruction, renal failure and or the need for
surgical or chemical bladder cautery or coagulation. A total of 72
